Results 221 to 230 of about 70,987 (344)

Review of recent molecular pathology of bladder urothelial carcinoma. [PDF]

Discov Oncol
Su P, Yang Y, Zheng H.
europepmc   +1 more source

Low-level Ki-67 expression as an independent predictor of bladder tumour recurrence in patients with primary upper tract urothelial carcinoma after radical nephroureterectomy [PDF]

, 2015
Pengjie Wu, Shengjie Liu, Wei Zhang, Yaoguang Zhang, Gang Zhu, Wei Dong, Ben Wan, Jianye Wang   +7 more
openalex   +1 more source

Spatial Multiomics Reveal Insights Into ADC Efficacy

European Journal of Immunology, Volume 56, Issue 5, May 2026.
Spatial multiomics profiling can reveal how tumor heterogeneity and microenvironment influence ADC efficacy. Combining spatial transcriptomics, proteomics, and AI‐based analysis improves the identification of tissue factors influencing therapy response.
Osman Goni, Niklas Klümper, Maria del Mar Muñiz Moreno, Markus Eckstein, Christoph Kuppe   +4 more
wiley   +1 more source

Analysis of the correlation between COL11A1 gene expression and clinical features in bladder urothelial carcinoma. [PDF]

Int J Clin Exp Pathol
Li J, Wang F, Wei X, Li P, Wang Q, Min H.   +5 more
europepmc   +1 more source

Urothelial carcinoma of the bladder presenting with abnormal inguinal metastasis

Hongyu Wang, Surong Hua
openalex   +1 more source

Correction to: Pictorial review of multiparametric MRI in bladder urothelial carcinoma with variant histology: pearls and pitfalls [PDF]

Yuki Arita, Sungmin Woo, Lisa Ruby, Thomas C. Kwee, Keisuke Shigeta, Ryo Ueda, Sunny Nalavenkata, Hiromi Edo, Kosuke Miyai, Jeeban P. Das, Pamela Causa Andrieu, Hebert Alberto Vargas   +11 more
openalex   +1 more source

Nanotechnology Meets Immunotherapy: Crosstalks Against Cancer

Immunity, Inflammation and Disease, Volume 14, Issue 5, May 2026.
ABSTRACT Background The convergence of nanotechnology and immunotherapy has ushered in a transformative era in cancer treatment, offering new strategies to overcome pharmacokinetic limitations and immune evasion associated with conventional therapies. While immunotherapy, spanning checkpoint inhibitors, adoptive cell transfer, and cancer vaccines, has ...
Nima Javanmehr, Asal Moazzami Ashtyani, Robabehbeygom Ghafelehbashi, Fateme Mousavi, Hossein Teimouri   +4 more
wiley   +1 more source

A Clinically Practical Nomogram for Predicting Survival in Elderly Patients (≥ 65 Years) With Bladder Urothelial Carcinoma: A Study Based on SEER Database and External Validation. [PDF]

Cancer Rep (Hoboken)
Wei J, Wei C, Chen J, Zhang X, Zhao W.
europepmc   +1 more source

E-cadherin and FGFR3 are risk factors determining prognosis of patients with bladder urothelial carcinoma. [PDF]

, 2023
Wentao Jing, Ye Cao, Huan Wang, Qian Dong   +3 more
openalex  

Secondary Colonic Adenocarcinoma After Continent Cutaneous Urinary Diversion a.m. Lundiana—An Aggressive Disease Entity With High Risk of Locally Advanced Disease and Metastases

IJU Case Reports, Volume 9, Issue 3, May 2026.
ABSTRACT Introduction We herein report two patients developing secondary adenocarcinomas arising in colonic segments used for urinary diversion a.m. Lundiana in a population‐based series 16 and 27 years after cystectomy, respectively. Case Presentation Following initial partial resection of the pouch, both patients experienced local recurrence; one ...
Fredrik Liedberg, Mats Bläckberg, Johannes Bobjer   +2 more
wiley   +1 more source